Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have received a consensus rating of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.33.

A number of equities analysts recently weighed in on MRVI shares. Wolfe Research assumed coverage on Maravai LifeSciences in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. Robert W. Baird dropped their target price on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. UBS Group boosted their price target on shares of Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a report on Thursday, August 8th. The Goldman Sachs Group lowered their price objective on shares of Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, October 8th. Finally, Wells Fargo & Company began coverage on Maravai LifeSciences in a report on Tuesday, August 27th. They issued an “overweight” rating and a $10.00 target price for the company.

Maravai LifeSciences Price Performance

Shares of NASDAQ:MRVI opened at $5.92 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The company has a market capitalization of $1.49 billion, a PE ratio of -3.61 and a beta of 0.02. The stock has a fifty day moving average of $7.16 and a 200-day moving average of $8.19. Maravai LifeSciences has a one year low of $4.28 and a one year high of $11.56.

Insider Activity at Maravai LifeSciences

In other Maravai LifeSciences news, insider Carl Hull acquired 175,000 shares of Maravai LifeSciences stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $5.64 per share, with a total value of $987,000.00. Following the completion of the purchase, the insider now owns 175,000 shares in the company, valued at $987,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.63% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MRVI. GAMMA Investing LLC increased its stake in shares of Maravai LifeSciences by 310.2% in the 2nd quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock valued at $26,000 after acquiring an additional 2,711 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Maravai LifeSciences during the 2nd quarter worth approximately $32,000. Blue Trust Inc. acquired a new position in Maravai LifeSciences during the second quarter valued at approximately $44,000. Venturi Wealth Management LLC bought a new stake in Maravai LifeSciences in the third quarter valued at approximately $47,000. Finally, Custom Index Systems LLC acquired a new stake in Maravai LifeSciences in the third quarter worth $97,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.